During the past decade, Neurology Associates PA conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 19 clinical trials were completed, i.e. on average, 76% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 11 clinical trials were completed. i.e. 110% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Neurology Associates PA" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "Allergan" with 3 trials sponsored, "Celgene" with 3 trials sponsored, "JANSSEN Alzheimer Immunotherapy Research & Development, LLC" with 3 trials sponsored and "Sunovion" with 3 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Neurology Associates PA" #1 collaborator was "Pfizer" with 3 trials as a collaborator, "Bayer" with 2 trials as a collaborator, "Acorda Therapeutics" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Mallinckrodt ARD Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Neurology Associates PA" are "Multiple Sclerosis" (12 trials), "Multiple Sclerosis, Relapsing-Remitting" (6 trials), "Relapsing Multiple Sclerosis" (4 trials), "Alzheimer's Disease" (3 trials) and "Cognition Disorders" (2 trials). Many other conditions were trialed in "Neurology Associates PA" in a lesser frequency.

Most popular intervention types in "Neurology Associates PA" are "Drug" (42 trials), "Biological" (4 trials), "Other" (4 trials), "Device" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Interferon beta-1a" (5 trials), "Ocrelizumab" (5 trials), "Eslicarbazepine acetate" (3 trials) and "Bapineuzumab 0.5 mg/kg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Neurology Associates PA" are 48 trials for "All" genders.

Currently, there are NaN active trials in "Neurology Associates PA". undefined are not yet recruiting, 5 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 33 completed trials in Neurology Associates PA, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Neurology Associates PA, 0 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".